These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21708465)

  • 1. Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition.
    Slavish PJ; Price JE; Jiang Q; Cui X; Morris SW; Webb TR
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4592-6. PubMed ID: 21708465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors.
    af Gennäs GB; Mologni L; Ahmed S; Rajaratnam M; Marin O; Lindholm N; Viltadi M; Gambacorti-Passerini C; Scapozza L; Yli-Kauhaluoma J
    ChemMedChem; 2011 Sep; 6(9):1680-92. PubMed ID: 21721129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
    Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of a novel tyrosine kinase inhibitor template.
    Jake Slavish P; Jiang Q; Cui X; Morris SW; Webb TR
    Bioorg Med Chem; 2009 May; 17(9):3308-16. PubMed ID: 19362847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screening and further development of novel ALK inhibitors.
    Okamoto M; Kojima H; Saito N; Okabe T; Masuda Y; Furuya T; Nagano T
    Bioorg Med Chem; 2011 May; 19(10):3086-95. PubMed ID: 21515061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Liu Z; Yue X; Song Z; Peng X; Guo J; Ji Y; Cheng Z; Ding J; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2014 Oct; 86():438-48. PubMed ID: 25200979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
    Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.
    Milkiewicz KL; Weinberg LR; Albom MS; Angeles TS; Cheng M; Ghose AK; Roemmele RC; Theroff JP; Underiner TL; Zificsak CA; Dorsey BD
    Bioorg Med Chem; 2010 Jun; 18(12):4351-62. PubMed ID: 20483621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminopyrimidinone cdc7 kinase inhibitors.
    Woods KW; Lai C; Miyashiro JM; Tong Y; Florjancic AS; Han EK; Soni N; Shi Y; Lasko L; Leverson JD; Johnson EF; Shoemaker AR; Penning TD
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1940-3. PubMed ID: 22326396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
    Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
    Puig de la Bellacasa R; Roué G; Balsas P; Pérez-Galán P; Teixidó J; Colomer D; Borrell JI
    Eur J Med Chem; 2014 Oct; 86():664-75. PubMed ID: 25222877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scaffold oriented synthesis. Part 2: Design, synthesis and biological evaluation of pyrimido-diazepines as receptor tyrosine kinase inhibitors.
    Gracias V; Ji Z; Akritopoulou-Zanze I; Abad-Zapatero C; Huth JR; Song D; Hajduk PJ; Johnson EF; Glaser KB; Marcotte PA; Pease L; Soni NB; Stewart KD; Davidsen SK; Michaelides MR; Djuric SW
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2691-5. PubMed ID: 18362070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The design, synthesis, and biological evaluation of PIM kinase inhibitors.
    Tsuhako AL; Brown DS; Koltun ES; Aay N; Arcalas A; Chan V; Du H; Engst S; Franzini M; Galan A; Huang P; Johnston S; Kane B; Kim MH; Laird AD; Lin R; Mock L; Ngan I; Pack M; Stott G; Stout TJ; Yu P; Zaharia C; Zhang W; Zhou P; Nuss JM; Kearney PC; Xu W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3732-8. PubMed ID: 22542012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.
    Donella-Deana A; Marin O; Cesaro L; Gunby RH; Ferrarese A; Coluccia AM; Tartari CJ; Mologni L; Scapozza L; Gambacorti-Passerini C; Pinna LA
    Biochemistry; 2005 Jun; 44(23):8533-42. PubMed ID: 15938644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment.
    Park CH; Choe H; Jang IY; Kwon SY; Latif M; Lee HK; Lee HJ; Yang EH; Yun JI; Chae CH; Cho SY; Choi SU; Ha JD; Jung H; Kim HR; Kim P; Lee CO; Yun CS; Lee K
    Bioorg Med Chem Lett; 2013 Nov; 23(22):6192-6. PubMed ID: 24095090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.